# 21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity., “Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible…”, is a CFR section of [21 CFR Part 314, Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5f6-71b1-905f-50e705df47c2); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter D—DRUGS FOR HUMAN USE](https://ontology.bommaritollc.com/id/01a0f094-b5e4-722f-99b0-5c1856aef2a9) › [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858) › [21 CFR Part 314, Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5f6-71b1-905f-50e705df47c2)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 314.510](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17aff4d2d872)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a2c7f3fb0e)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e325-7402-9a1d-3c88ff46cffd)
  - [evidence from https://www.govinfo.gov/link/cfr/21/314?sectionnum=510&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-67d3-77cb-a9a2-dbd016de92f3)
- `schema:isPartOf`: [21 CFR Part 314, Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5f6-71b1-905f-50e705df47c2)
- `schema:legislationIdentifier`: 21 CFR 314.510
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/314?sectionnum=510&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/314?sectionnum=510&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/314?sectionnum=510&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (4; `eli:cites`):
  - [21 CFR 201.57 Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1).](https://ontology.bommaritollc.com/id/01a0f094-c333-77df-9523-a7dc0b2a5cb0)
  - [21 CFR 314.530 Withdrawal procedures.](https://ontology.bommaritollc.com/id/01a0f094-c4e6-7632-ad2f-fa2a85282d49)
  - [21 CFR 314.560 Termination of requirements.](https://ontology.bommaritollc.com/id/01a0f094-c4e8-72cc-9503-15d6a6160e88)
  - [21 U.S.C. 356b Reports of postmarketing studies](https://ontology.bommaritollc.com/id/01a0f06c-ccea-769f-b60a-251047e97ffa)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62)
Cite as: 21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
